RxDoctor Payments Data

Brittany Perry, APRN

Psychiatric/Mental Health · West Lafayette, INNPI 1730724295

Payments from drug & device makers

$1,500in general payments, 2019–2025

Across 85 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$484
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$235
  • Alkermes, Inc.$168
  • Otsuka America Pharmaceutical, Inc.$148
  • Axsome Therapeutics, Inc.$93
  • Corium, LLC$62
  • plus $311 from 9 others

What the payments were for

  • Food & beverage$1,500100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,500 in reported general payments places this provider in the 65th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$5,888
Medicare patients
25
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl43$62,221
Invega SustennaPaliperidone Palmitate15$57,619
LybalviOlanzapine/Samidorphan Malate26$40,451
CaplytaLumateperone Tosylate17$29,252
TrintellixVortioxetine Hydrobromide38$27,733
RexultiBrexpiprazole12$19,844
Paroxetine Hcl14$6,861
Aripiprazole33$6,186
Ramelteon17$4,836
Duloxetine Hcl116$2,766
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine73$2,654
Olanzapine42$2,273
Buspirone Hcl110$1,276
Haloperidol27$1,274
Fluoxetine Hcl48$1,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$484$62,22143 claims
Johnson & JohnsonInvega Sustenna$45$57,61915 claims
Alkermes, Inc.Lybalvi$168$40,45126 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$235$29,25217 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$54$27,73338 claims
Otsuka America Pharmaceutical, Inc.Rexulti$148$19,84412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in West Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →